Virion-associated Vpr of human immunodeficiency virus type 1 triggers activation of apoptotic events and enhances fas-induced apoptosis in human T cells.
Human immunodeficiency virus type 1 (HIV-1) Vpr protein exists in three different forms: soluble, intracellular, and virion associated. Previous studies showed that virion-associated Vpr induces apoptosis in activated peripheral blood mononuclear cells (PBMCs) and Jurkat T cells, but these studies were conducted in the presence of other de novo-expressed HIV proteins that may have had additive proapoptotic effects. In this report, we show that virion-associated Vpr triggers apoptosis through caspases 3/7 and 9 in human T cells independently of other HIV de novo-expressed proteins. In contrast to a previous study, we also detected the activation of caspase 8, the initiator caspase of the death receptor pathway. However, activation of all caspases by virion-associated Vpr was independent of the Fas death receptor pathway. Further analyses showed that virion-associated Vpr enhanced caspase activation in Fas-mediated apoptosis in Jurkat T cells and human activated PBMCs. Thus, our results indicate for the first time that viral particles that contain virion-associated Vpr can cause apoptosis in the absence of other de novo-expressed viral factors and can act in synergy with the Fas receptor pathway, thereby enhancing the apoptotic process in T cells. These findings suggest that virion-associated Vpr can contribute to the depletion of CD4(+) lymphocytes either directly or by enhancing Fas-mediated apoptosis during acute HIV-1 infection and in AIDS.
Arokium
Hubert
H
Department of Microbiology, Immunology and Molecular Genetics, University of California at Los Angeles, David Geffen School of Medicine, 615 Charles E. Young Dr. South, BSRB 173, Los Angeles, CA 90095, USA.
Kamata
Masakazu
M
Chen
Irvin
I
D000818:Animals; D017209:Apoptosis / Q000276:immunology*; D020169:Caspases / Q000378:metabolism; D002453:Cell Cycle / Q000502:physiology; D002460:Cell Line; D004789:Enzyme Activation; D015658:HIV Infections / Q000276:immunology; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D007963:Leukocytes, Mononuclear / Q000166:cytology / Q000276:immunology; D013601:T-Lymphocytes / Q000166:cytology / Q000276:immunology*; D014771:Virion / Q000378:metabolism*; D019014:fas Receptor / Q000276:immunology*; D054325:vpr Gene Products, Human Immunodeficiency Virus / Q000235:genetics / Q000276:immunology*
D019014:fas Receptor; D054325:vpr Gene Products, Human Immunodeficiency Virus; C514912:vpr protein, Human immunodeficiency virus 1; D020169:Caspases
Blood. 1999 May 1;93(9):3053-63
10216102
Virology. 1995 Feb 1;206(2):935-44
7531918
Virology. 2007 Mar 15;359(2):243-52
17056089
Blood. 1999 Feb 1;93(3):1000-10
9920849
Virology. 2000 Oct 10;276(1):16-26
11021990
Cell Death Differ. 2003 Jan;10(1):26-35
12655293
Oncogene. 2002 Jul 11;21(30):4613-25
12096338
Proc Natl Acad Sci U S A. 2006 Feb 28;103(9):3369-74
16492778
Blood. 1997 Mar 15;89(6):2060-6
9058728
J Virol. 2008 Jun;82(12):5672-82
18385244
J Immunol. 2003 Mar 1;170(5):2629-37
12594291
Apoptosis. 2007 May;12(5):803-13
17294081
PLoS Pathog. 2006 Dec;2(12):e127
17140287
Nature. 1995 Jun 8;375(6531):497-500
7539892
J Virol. 1995 Nov;69(11):6705-11
7474080
J Acquir Immune Defic Syndr (1988). 1990;3(1):11-8
2136707
Apoptosis. 2003 Mar;8(2):115-28
12766472
J Biol Chem. 2007 Sep 14;282(37):27046-27057
17620334
J Virol. 1996 Jan;70(1):199-206
8523526
Nature. 1988 Jun 2;333(6172):457-61
3374586
Cell. 1998 Aug 21;94(4):481-90
9727491
J Biol Chem. 1999 Mar 26;274(13):9083-91
10085158
Cell Death Differ. 2002 Nov;9(11):1212-9
12404120
J Immunol. 1997 Mar 1;158(5):2456-63
9036997
J Virol. 1997 Jul;71(7):5579-92
9188632
Genes Dev. 1998 Jan 15;12(2):175-85
9436978
J Virol. 1995 Nov;69(11):6873-9
7474102
Nat Med. 1997 Oct;3(10):1117-23
9334723
Immunology. 1996 Apr;87(4):581-5
8675212
Biochem Biophys Res Commun. 2006 Sep 29;348(3):1101-6
16904642
Science. 2001 Nov 2;294(5544):1105-8
11691994
J Neurovirol. 2002 Apr;8(2):86-99
11935461
Nature. 2005 Apr 28;434(7037):1093-7
15793563
Proc Natl Acad Sci U S A. 1994 Nov 8;91(23):10873-7
7971975
J Virol. 1999 Jan;73(1):592-600
9847364
J Virol. 2000 Apr;74(7):3105-11
10708425
Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9571-6
8790371
J Exp Med. 2001 Feb 19;193(4):509-19
11181702
J Virol. 1995 Oct;69(10):6304-13
7666531
J Clin Invest. 2003 May;111(10):1547-54
12750404
J Virol. 1999 Jan;73(1):92-100
9847311
J Virol. 1998 Jun;72(6):4686-93
9573232
Nat Rev Immunol. 2003 Sep;3(9):745-56
12949498
Blood. 1996 Sep 1;88(5):1741-6
8781430
J Biol Chem. 2002 Oct 4;277(40):37820-31
12095993
J Virol. 2007 Apr;81(8):4367-70
17267494
J Virol. 2000 Oct;74(20):9717-26
11000244
Oncogene. 1996 Aug 1;13(3):487-93
8760290
Annu Rev Cell Dev Biol. 2005;21:35-56
16212486
J Biol Chem. 1999 Jan 15;274(3):1541-8
9880531
Clin Dev Immunol. 2007;2007:93462
18317535
J Virol. 2008 Sep;82(18):9265-72
18596088
EMBO J. 1998 Mar 16;17(6):1675-87
9501089
J Immunol. 1996 Mar 15;156(6):2282-93
8690919
Mol Biol Cell. 2004 Apr;15(4):1793-801
14767062
Cytometry. 1995 Jun 15;22(2):111-4
7587741
Virology. 2001 Jul 5;285(2):181-92
11437653
Cell. 2004 Jan 23;116(2):205-19
14744432
Proc Natl Acad Sci U S A. 1998 Apr 14;95(8):4595-600
9539783
Nat Med. 1995 Feb;1(2):129-34
7585008
J Intern Med. 2005 Dec;258(6):479-517
16313474
J Clin Invest. 1998 Jul 1;102(1):79-87
9649560
Cancer Res. 2006 Jan 15;66(2):627-31
16423988
J Virol. 1996 Apr;70(4):2516-24
8642681
Oncogene. 2000 Sep 21;19(40):4563-73
11030145
AIDS. 1996 Feb;10(2):131-41
8838700
J Exp Med. 1998 Sep 7;188(5):979-84
9730899
AIDS. 2000 May 26;14(8):939-49
10853975
J Virol. 1999 May;73(5):4101-9
10196306
Cell. 1998 Aug 21;94(4):491-501
9727492
EMBO J. 1992 Sep;11(9):3405-12
1324171
Science. 1995 Apr 21;268(5209):429-31
7716549
Proc Natl Acad Sci U S A. 1999 Oct 12;96(21):12039-43
10518572
Nature. 2005 Apr 28;434(7037):1148-52
15793562
Virology. 1994 May 1;200(2):623-31
8178448
J Exp Med. 2000 Jan 3;191(1):33-46
10620603
J Virol. 1995 Nov;69(11):6859-64
7474100